国际投行报告-中国医疗保健行业-2022年中国医疗保健展望：冬天来了，春天还会远吗？-2022.1.5-87页

539

国际投行报告-中国医疗保健行业-2022年中国医疗保健展望：冬天来了，春天还会远吗？-2022.1.5-87页

# 投行报告 # 医疗保健行业 # 2022年大小：5.12M | 页数：87 | 上架时间：2022-01-14 | 语言：英文

国际投行报告-中国医疗保健行业-2022年中国医疗保健展望：冬天来了，春天还会远吗？-2022.1.5-87页.pdf

免费阅读10页，购买之后可查看、下载87页完整报告

国际投行报告-中国医疗保健行业-2022年中国医疗保健展望：冬天来了，春天还会远吗？-2022.1.5-87页.pdf

试看10页

类型: 行研

上传者: YXM-187

撰写机构: CREDIT SUISSE

出版日期: 2022-01-05

摘要：

Top Stock Picks Our top picks going into 2022 are WuXi Biologics, BeiGene, and I-Mab Biopharma.

– Wuxi Bio (OUTPERFORM, TP of HK$151): We continue to like Wuxi’s business as not only is it the leading biologics CRO/CMO company in China, but also its significant R&D outsourcing demand should keep Wuxi Bio busy.

– BeiGene (OUTPERFORM, TP of US$400): We continue to like BeiGene as we see the company as a formidable player that has one the of strongest globalisation potential among China biotech industry.

– I-Mab (OUTPERFORM, TP of US$90): We like I-Mab as we see that the company's differentiated global and China pipelines have near-term visibility of large potential catalysts.

展开>> 收起<<

请登录，再发表你的看法

YXM-187

关注